IP Library › Granted Patent US 12,226,149
Granted Patent B2
US 12,226,149 · App. 17/234,414 · Granted Feb 18, 2025

System and method for adjusting available power per probe during an ablation procedure

Inventors: Lisa M. McGregor (Chamblee, GA); Lee Rhein (Hollywood, FL); Tyler W. Crone (Atlanta, GA); Jennifer J. Barrett (Alpharetta, GA)
Assignee: Avent, Inc.
A61B18/1492A61B18/1206A61B2018/00577A61B2018/00702A61B2018/00714A61B2018/00797
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,149
App. No.
17/234,414
Granted
Feb 18, 2025
Kind
B2
Abstract

An ablation system for treating tissue in a patient's body includes an energy source, one or more probes connected to the energy source, and a controller communicatively coupled to one or more probes. Each of the probes includes an elongate member having a distal region with an electrically non-conductive outer circumferential portion and a proximal region. The probes further include an electrically conductive energy delivery device extending distally from the electrically non-conductive outer circumferential portion. The controller includes one or more processors and one or more memory devices. The one or more memory devices are configured to store computer-readable instructions that when executed by the one or more processors cause the one or more processors to perform operations that include detecting a number of probes connected to the energy source and allocating a portion of the predetermined power supply to each of the probes.

Claims (37)

1. A method of treating tissue of a patient's body, the method comprising:

providing an energy source and a controller coupled to a probe assembly, the energy source comprising a predetermined power supply;

detecting, via the controller, a number of probes of the probe assembly connected to the energy source, each probe having an electrically-conductive energy delivery device for delivering one of electrical and radiofrequency (RF) energy to the patient's body;

positioning the probes at or near the tissue to be treated of the patient's body;

dividing, via the energy source, the predetermined power supply among each of the probes based on the number of probes detected; and

treating the tissue by independently controlling each of the probes using the divided power, wherein each of the probes is controlled in a ready state where a thermocouple measurement of a connected probe is detectable and the connected probe is not delivering power,

wherein individual treatment procedures for each of the probes are independently started or stopped without affecting available power to remaining probes.

2. The method of claim 1 , wherein in the ready state, providing one or more bursts of low-voltage output to at least one of the probes such and measuring at least one of a corresponding RF voltage and current.

3. The method of claim 2 , further comprising determining at least one of an impedance and a temperature of the corresponding probe as a function of a measured RF voltage and current.

4. The method of claim 1 , wherein treating the tissue by independently controlling each of the probes using the divided power further comprises controlling power supplied to each of the probes as a function of a temperature of that probe.

5. The method of claim 1 , wherein the probes include a first probe and a second probe,

wherein treating the tissue by independently controlling each of the probes based on the divided power further comprises controlling the first and second probes in an on state, where in the on state the thermocouple measurement of the connected probe is detectable and the connected probe is delivering power, and the RF energy is delivered from each of the first and second probes for a corresponding first and second time period,

wherein, in the on state, an amplitude of the RF energy delivered the first and second probe is controlled by a corresponding temperature of the first and second probe.

6. The method of claim 1 , wherein treating the tissue by independently controlling each of the probes based on the divided power further comprises cycling through a treatment procedure for one or more of the probes, wherein cycling through the treatment procedure for one or more of the probes further comprises delivering energy from the energy source to each of the probes in succession.

7. The method of claim 6 , wherein, when cycling through the treatment procedure for one or more of the probes, the method omits cycling through probes that do not have an available power above a certain threshold.

8. The method of claim 1 , further comprising activating the individual treatment procedures for each of the probes in at least one of a sequential order or simultaneously.

9. The method of claim 1 , wherein treating tissue by independently controlling each of the probes further comprises limiting the power provided to a pair of the probes to a threshold power amount such that the pair of probes operate in a bipolar mode.

10. An ablation system for treating tissue in a patient's body, the ablation system comprising:

an energy source comprising a predetermined power supply;

one or more probes connected to the energy source, each comprising an electrically conductive energy delivery device for delivering one of electrical and radiofrequency (RF) energy to the patient's body;

a controller communicatively coupled to one or more probes, the controller including a processor and a memory device, the memory device configured to store computer-readable instructions that when executed by the processor cause the processor to perform operations, the operations comprising:

detecting a number of probes connected to the energy source; and

dividing the predetermined power supply among each of the probes based on the number of probes detected; and

treating the tissue by independently controlling each of the probes using the divided power, wherein each of the probes is controlled in a ready state where a thermocouple measurement of a connected probe is detectable and the connected probe is not delivering power,

wherein individual treatment procedures for each of the probes are independently started or stopped without affecting available power to remaining probes.

11. The ablation system of claim 10 , wherein in the ready state, one or more bursts of low-voltage output is provided to at least one of the probes such that at least one of a corresponding RF voltage and current can be measured.

12. The ablation system of claim 11 , wherein the controller operations further include:

determining at least one of an impedance and a temperature of the corresponding probe as a function of a measured RF voltage and current.

13. The ablation system of claim 10 , wherein treating the tissue by independently controlling each of the probes based on the divided power further comprises controlling power supplied to each of the probes as a function of a temperature of that probe.

14. The ablation system of claim 10 , wherein the probes include a first probe and a second probe,

wherein the first and second probes are controlled in an on state, where in the on state the thermocouple measurement of the connected probe is detectable and the connected probe is delivering power, and the RF energy is delivered from each of the first and second probes for a corresponding first and second time period,

wherein, in the on state, an amplitude of the RF energy delivered the first and second probe is controlled by a corresponding temperature of the first and second probe.

15. The ablation system of claim 10 , wherein treating the tissue by independently controlling each of the probes based on the divided power further comprises cycling through a treatment procedure for each of the probes, wherein cycling through the treatment procedure for one or more of the probes further comprises delivering energy from the energy source to each of the probes in succession.

16. The ablation system of claim 15 , further comprising omitting treatment procedures for probes that do not have an available power above a certain threshold.

17. The ablation system of claim 10 , further comprising limiting the power provided to a pair of the probes to a threshold power amount such that the pair of probes operate in a bipolar mode.

18. The ablation system of claim 10 , wherein the electrically conductive energy delivery device of each at least one of the one or more probes extends distally from an electrically non-conductive outer circumferential portion.

19. The ablation system of claim 10 , wherein the number of probes comprises from one probe to four probes and the energy source comprises a generator, the predetermined power supply of the generator comprising at least 80 watts.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 28, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AVENT, INC.; AVANOS MEDICAL SALES, LLC
Reel/Frame 076077/0108 →
SECURITY INTEREST Recorded Jul 27, 2026
From: AVENT, INC.
To: GOLUB CAPITAL MARKETS LLC, AS COLLATERAL AGENT
Reel/Frame 076066/0888 →
SECURITY INTEREST Recorded Jun 24, 2022
From: AVENT, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060441/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2021
From: MCGREGOR, LISA M.; RHEIN, LEE; CRONE, TYLER W.; BARRETT, JENNIFER J.
To: AVENT, INC.
Reel/Frame 056055/0857 →
Continuity (2)
Continuation 16027653 · Jul 5, 2018
Related Publication 20210236200A1 · Aug 5, 2021
References Cited (34)
US 5542916A · Hirsch et al. · 1996 [cited by applicant]
US 5718701A · Shai et al. · 1998 [cited by applicant]
US 5957961A · Maguire et al. · 1999 [cited by applicant]
US 6231569B1 · Bek et al. · 2001 [cited by applicant]
US 6346104B2 · Daly et al. · 2002 [cited by applicant]
US 6470219B1 · Edwards et al. · 2002 [cited by applicant]
US 7125407B2 · Edwards et al. · 2006 [cited by applicant]
US 8486065B2 · Lee et al. · 2013 [cited by applicant]
US 8771269B2 · Sherman et al. · 2014 [cited by applicant]
US 8998893B2 · Avitall · 2015 [cited by applicant]
US 9044245B2 · Condie et al. · 2015 [cited by applicant]
US 9168093B2 · Mihalik et al. · 2015 [cited by applicant]
US 9375154B2 · Wang · 2016 [cited by applicant]
US 9387032B2 · Martin et al. · 2016 [cited by applicant]
US 9539052B2 · Edwards et al. · 2017 [cited by applicant]
US 9561070B2 · Brotz et al. · 2017 [cited by applicant]
US 20080065062A1 · Leung et al. · 2008 [cited by applicant]
US 20080097557A1 · Eggers et al. · 2008 [cited by applicant]
US 20080183169A1 · Klimovitch · 2008 [cited by examiner]
US 20080234574A1 · Hancock · 2008 [cited by examiner]
US 20090138011A1 · Epstein · 2009 [cited by applicant]
US 20100324548A1 · Godara et al. · 2010 [cited by applicant]
US 20130165919A1 · Epstein · 2013 [cited by applicant]
US 20130331835A1 · Leung et al. · 2013 [cited by applicant]
US 20140243823A1 · Godara et al. · 2014 [cited by applicant]
US 20140276755A1 · Cao et al. · 2014 [cited by applicant]
US 20140330266A1 · Thompson et al. · 2014 [cited by applicant]
US 20150133917A1 · Edwards et al. · 2015 [cited by applicant]
US 20170049513A1 · Cosman, Jr. · 2017 [cited by examiner]
US 20200085487A1 · Godara et al. · 2020 [cited by applicant]
EP 2653128 · 2013 [cited by applicant]
EP 2942023 · 2015 [cited by applicant]
WO 2018116247 · 2018 [cited by applicant]
International Search Report and Written Opinion issued for Application No. PCT/US2019/040229, dated Oct. 16, 2019, 18 pages. [cited by applicant]